$99,315,090

Department of Health and Human Services·Office of Assistant Secretary for Preparedness and Response

to PARTNER THERAPEUTICS, INC.

healthactiveONGOING · MOD OF 2023 CONTRACT

WORK BEGAN2023-09-26·LATEST ACTION2026-03-26·SOURCEUSASPENDING·SOURCE IDCONT_AWD_75A50323F80027_7505_36F79723D0171_3600

Award description

LEUKINE 250MCG VIL INJ (5PKG)

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

Procurement of Leukine (sargramostim) injectable medication under an ongoing HHS preparedness contract that began in September 2023.

Sub-sectors

pharmaceutical-procurementemergency-preparednesssargramostim-leukine

Why this matters

Leukine is a granulocyte-macrophage colony-stimulating factor used in cancer treatment and immune recovery; stockpiling supports biodefense and pandemic preparedness readiness.

Supply-chain signal

Large-scale pharmaceutical procurement signals sustained demand for sargramostim manufacturing capacity and cold-chain distribution infrastructure.

U.S.–China competition angle

Domestic pharmaceutical manufacturing for critical biologics reduces reliance on foreign supply chains for emergency medical countermeasures.

Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-05-28. Cost: $0.002982.

Period of performance

Start

2023-09-26

End

2027-03-29

Status

activein 258 days

Recipient

PARTNER THERAPEUTICS, INC.

UEI J33MSDBJZMC6

View full profile →

Sources

USAspending.gov — all awards for this UEI →
SAM.gov entity registration →
Award record ingested from usaspending. Source identifier CONT_AWD_75A50323F80027_7505_36F79723D0171_3600.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.